IGF-I assay methods and biologic variability: evaluation of acromegaly treatment response

Author:

Clemmons David R1ORCID,Bidlingmaier Martin2ORCID

Affiliation:

1. Department of Medicine, UNC School of Medicine , Chapel Hill, NC 27599 , United States

2. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München , Munich 81377 , Germany

Abstract

Abstract Serum insulin-like growth factor (IGF-I) is the primary biochemical measure of disease activity in patients with acromegaly, and the 2014 Endocrine Society guidelines recommended normal age-adjusted serum IGF-I as the biochemical target of treatment. However, quantification and interpretation of IGF-I levels are subject to limitations that may affect therapeutic decisions. Techniques for measuring IGF-I have evolved greatly over the past 40 years and continue to do so. Results can vary substantially for different assays, procedures, and laboratories. For any assay, the interpretation of IGF-I values requires robust reference ranges. Using currently available large normative databases, the upper limit of normal (ULN) for IGF-I in middle-aged and elderly individuals is lower than historical reference ranges. Thus, the goal of achieving IGF-I < 1× ULN is more demanding than in the past, and some patients with acromegaly who were classified as “normal” (IGF-I < 1× ULN) in previous studies would be reclassified as above the ULN based on newer normative data. In addition, substantial intra-individual, week-to-week variation in serum IGF-I levels (unrelated to assay performance) has been observed. With changes over time in the measurement of IGF-I and the advent of updated reference ranges derived from large normative databases, it is difficult to justify rigid adherence to the goal of maintaining IGF-I below the ULN for all patients with acromegaly. Instead, symptoms, comorbidities, and quality of life should be considered, along with growth hormone and IGF-I levels, when evaluating the need for further treatment.

Funder

Crinetics Pharmaceuticals

Publisher

Oxford University Press (OUP)

Reference28 articles.

1. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals;Zadik;J Clin Endocrinol Metab,1985

2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly;Swearingen;J Clin Endocrinol Metab,1998

3. Mortality in patients with pituitary disease;Sherlock;Endocr Rev,2010

4. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly;Holdaway;Eur J Endocrinol,2008

5. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis;Bolfi;Eur J Endocrinol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3